NCT07037849 The Effects of the Control Strategies of Wearable Lower Limb Rehabilitation Robots
| NCT ID | NCT07037849 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Eighth Affiliated Hospital, Sun Yat-sen University |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2024-10-23 |
| Primary Completion | 2026-10-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2024-10-23 with a primary completion date of 2026-10-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Post-stroke patients were required to complete a session of robot-assisted training, which involved nine repetitions of 5-meter overground walking (three trials for each of the three controllers) in a rectangular hospital corridor.
Eligibility Criteria
Inclusion Criteria: Stroke patients aged between 18 and 75 years. Patients who are medically stable and able to stand and walk independently for at least 10 meters during rehabilitation. Stroke event occurred at least 3 months ago Patients with impaired lower limb motor function but with some degree of muscle activity in the lower extremities. Patients without severe cognitive impairment and capable of understanding and following the treatment protocol. Patients without severe balance or coordination disorders, able to maintain balance and perform gait training with assistive devices. Patients without lower limb fractures or other serious skeletal issues affecting the lower limbs. Patients without severe cardiovascular or other serious illnesses and able to tolerate the intensity and duration of rehabilitation therapy. Patients willing to participate in the study and able to provide written informed consent. Exclusion Criteria: Severe cognitive impairment that prevents the patient from understanding or complying with the treatment protocol. Severe balance or coordination disorders that prevent the patient from maintaining balance and participating in gait training, even with assistive devices. Other serious motor disorders, such as abnormal muscle tone or ataxia, which may interfere with the effectiveness of rehabilitation therapy. Active cardiovascular disease or other serious systemic illnesses that may affect the patient's safety or treatment outcomes. Lower limb fractures or other serious skeletal issues that may impact the suitability and safety of robot-assisted rehabilitation therapy. Patients currently receiving other rehabilitation or experimental treatments. Patients with skin ulcers, infections, or other severe skin conditions that may interfere with the use and application of robotic devices. Unexplained discomfort or pain symptoms that may limit the patient's ability to participate in rehabilitation therapy. Failure to meet other specific inclusion criteria outlined in the study protocol.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07037849 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07037849 currently recruiting?
Yes, NCT07037849 is actively recruiting participants. Contact the research team at zhaosf1@163.com for enrollment information.
Where is the NCT07037849 trial being conducted?
This trial is being conducted at Shenzhen, China.
Who is sponsoring the NCT07037849 clinical trial?
NCT07037849 is sponsored by Eighth Affiliated Hospital, Sun Yat-sen University. The trial plans to enroll 10 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.